PRESS RELEASE
Release date: 4 September 2024
Embargoed until: 07:00 am
CLS Holdings plc ("CLS" or the "Group")
CLS leases over 8,900 sqm in
CLS announces it has let 8,939 sqm (96,219 sq. ft) at Fangdieckstrasse 75 in
The HPH Institute, which specialises in the diagnosis of haematological diseases, has extended its existing lease of 5,628 sqm (60,579 sq. ft) of office and laboratory space until 2035 and has leased an additional 3,311 sqm (35,639 sq. ft) of office and production space in the property. The HPH Institute will move into the additional space from September 2024, following the current occupier's lease surrender, meaning the property will remain fully let.
Fangdieckstrasse 75 was acquired by CLS in 2007 and has since been fully refurbished and successfully repositioned as a science and healthcare hub. The multi-tenant property has 13,092 sqm (140,921 Sq. ft) and offers a mix of office, light industrial, and laboratory space.
Located close to the 'Science City Hamburg Bahrenfeld' area of
Fredrik Widlund, Chief Executive Officer of CLS, commented:
"We are thrilled that HPH has not only extended their existing lease for over 10 years but has also chosen to lease additional space in Fangdieckstrasse 75. Hamburg-Bahrenfeld is an up-and-coming commercial area and CLS has successfully repositioned the property as an attractive location for science and technology organisations, and demand from occupiers in this sector remains high."
-ENDS-
For further information, please contact:
CLS Holdings plc
(LEI: 213800A357TKB2TD9U78)
Fredrik Widlund, Chief Executive Officer
Andrew Kirkman, Chief Financial Officer
+44 (0)20 7582 7766
Media Contact:
Edelman Smithfield (Financial PR)
Alex Simmons
+44 7970 174 353
Hastings Tarrant
+44 7813 407 665
Broker Contacts:
Panmure Liberum
Jamie Richards
David Watkins
+44 (0)20 3100 2000
Berenberg
Matthew Armitt
Richard Bootle
+44 (0) 203 207 7800
Registered in England No. 2714781. Registered Office as above
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.